Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYUREA versus XATMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYUREA versus XATMEP.
HYDROXYUREA vs XATMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S phase; also increases fetal hemoglobin production by inducing nitric oxide and altering erythroid progenitor signaling.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate and thereby inhibiting DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through inhibition of purine metabolism and adenosine accumulation.
Oral: 15-20 mg/kg once daily (rounded to nearest 500 mg) for myeloproliferative disorders (e.g., essential thrombocythemia); 80 mg/kg every 3 days (as 35 mg/kg single dose) for sickle cell disease.
Methotrexate 10 mg orally once weekly; maximum 25 mg per week.
None Documented
None Documented
Clinical Note
moderateHydroxyurea + Digoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateHydroxyurea + Digitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateHydroxyurea + Deslanoside
"Hydroxyurea may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateHydroxyurea + Acetyldigitoxin
"Hydroxyurea may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3.5–4.5 hours; clinical context: hematologic effects persist for 24-48 hours due to irreversible inhibition of ribonucleotide reductase.
The terminal elimination half-life of methotrexate is approximately 3-10 hours for low doses (<50 mg/m²) and 8-15 hours for high doses (≥500 mg/m²). Prolonged half-life (>24 hours) is associated with renal impairment and drug accumulation, increasing toxicity risk.
Renal: approximately 80% (30-60% unchanged; remainder as metabolites). Fecal: <10%.
Methotrexate is primarily eliminated renally via glomerular filtration and active tubular secretion. Approximately 80-90% of the dose is excreted unchanged in urine within 24 hours. Fecal excretion is minimal (<10%), with biliary elimination accounting for a small fraction.
Category A/B
Category C
Antimetabolite
Antimetabolite